The percentage on each card is OGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● Business WireNov 12, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
JERSEY CITY, N.J.--(BUSINESS WIRE)--ACAAI- new pooled post-hoc analysis of VTAMA (tapinarof) cream, 1% demonstrates consistent response for atopic dermatitis disease severity and itch.…
● Zacks Investment ResearchNov 10, 2026 · 10:01 ET
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…
● Defense WorldNov 3, 2026 · 03:45 ETEARNINGS EXPECTED BY FEB 16
Contrasting CASI Pharmaceuticals (NASDAQ:CASI) and Organon & Co. (NYSE:OGN)
Organon and Co. (NYSE: OGN - Get Free Report) and CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strengt…
● Zacks Investment ResearchOct 30, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 16
Organon (OGN) Q3 Earnings and Revenues Top Estimates
Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.…
● Business WireOct 19, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financia…
Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength…
● Business WireOct 16, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.…
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.…
● Business WireOct 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.…
● Defense WorldSep 15, 2026 · 04:02 ETEARNINGS EXPECTED BY FEB 16
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $770,000 Investment in Organon & Co. $OGN
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Organon and Co. (NYSE: OGN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 56,850 shares of the compan…
● Business WireSep 14, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.…
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…
● Defense WorldAug 29, 2026 · 04:12 ETEARNINGS EXPECTED BY FEB 16
Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN
Bank of America Corp DE reduced its position in shares of Organon and Co. (NYSE: OGN) by 58.5% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 738,502 …
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from O…
Organon & Co. (NYSE:OGN) Sets New 52-Week High – Still a Buy?
Organon and Co. (NYSE: OGN - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock…
Article counts from the last market-wide feed page, across every symbol we track and not just OGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.